In addition, it has been demonstrated that targeting aPKC-ι/λ suppresses Hh pathway signalling and proliferation of BCC cell lines resistant to the SMO inhibitor Vismodegib [64]. The gene discussed is SMO; the disease is skin basal cell carcinoma.